Astrazeneca Pharma India Ltd vs Hester Biosciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8217 as of 30 Apr 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Hester Biosciences Ltd changed from 47.4 on March 2021 to 38.8 on March 2025 . This represents a CAGR of -3.92% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Hester Biosciences Ltd changed from ₹ 1630 crore on March 2021 to ₹ 1066 crore on March 2025 . This represents a CAGR of -8.14% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Hester Biosciences Ltd for the Dec '25 is ₹ 79.4 crore as compare to the Sep '25 revenue of ₹ 82.85 crore. This represent the decline of -4.16% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Hester Biosciences Ltd for the Dec '25 is ₹ 19.78 crore as compare to the Sep '25 ebitda of ₹ 23.6 crore. This represent the decline of -16.19% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Hester Biosciences Ltd changed from ₹ 7.49 crore to ₹ 9.31 crore over 7 quarters. This represents a CAGR of 13.24% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Hester Biosciences Ltd changed from 21.33 % on March 2021 to 18.71 % on March 2025 . This represents a CAGR of -2.59% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Hester Biosciences Ltd

Hester Biosciences Limited is one of the leading and pioneering animal healthcare companies in India.
The Company was incorporated in April, 1987 and is engaged in manufacturing of Poultry vaccines and Large Animal Vaccines and trading of Poultry and Large animal and Petcare health products having its manufacturing set up at Meda Adraj Village, Mehsana District, Gujarat. The Company built a presence in several regions of Africa and in numerous nations, including Vietnam, Indonesia, Nepal, and Bangladesh.
The products and services included over 51 vaccines and 70+ health products.
In addition, it offers a vast selection of pharmaceuticals, feed supplements, and disinfectants for poultry and large animals. The Company markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Hester Biosciences Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Hester Biosciences Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,543 Cr while Market cap of Hester Biosciences Ltd is 1,393 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Hester Biosciences Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Hester Biosciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Hester Biosciences Ltd?

As of May 4, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8217.2. On the other hand, Hester Biosciences Ltd stock price is INR ₹1638.3.

How do dividend payouts of Astrazeneca Pharma India Ltd and Hester Biosciences Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Hester Biosciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.